

In re Application of: WALLACH et al

Application No.: 08/485,129

Filed: June 7, 1995

For: ISOLATED DNA ENCODING TUMOR NECROSIS FACTOR ...



THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Sig:

Transmitted herewith is an [XX] Amendment [ ] in the above-identified application.

[ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

[X] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

[ ] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
TOTAL	* 18	MINUS	** 21	= 0	x 9	\$		x 18	\$
INDEP.	* 5	MINUS	*** 4	= 1	x 39	\$		x 78	\$ 78.00
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+130	\$		+ 260	\$
					TOTAL	\$		TOTAL	\$ 78.00

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

4 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[ ] First - \$ 55.00

[ ] Second - \$190.00

[ ] Third - \$435.00

[ ] Fourth - \$680.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[ ] First - \$ 110.00

[ ] Second - \$ 380.00

[ ] Third - \$ 870.00

[ ] Fourth - \$1360.00

Month After Time Period Set

RECEIVED

AUG 27 2000

TECH CENTER 1600/2900

[ ] Less fees (\$ ) already paid for month(s) extension of time on .

[X] Please charge my Deposit Account No. 02-4035 in the amount of \$ .

[XX] A check in the amount of \$78.00 is attached (check no. 22369).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

15/07/2000 11:00 00000002 01485129

01 02 000

70.00 00

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:

ROGER L. BROWDY


Registration No. 25,618

Facsimile: (202) 737-3528

Telephone: (202) 628-5197

RLB:al

37,971



RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OK to enter  
ABS  
6/19/99

In re Application of:	)	Art Unit: 1644
David WALLACH et al	)	Examiner: R. Schwadron
Appln. No.: 08/485,129	)	Washington, D.C.
Filed: June 7, 1995	)	May 25, 1999
For: ISOLATED DNA ENCODING TUMOR	)	Atty.Docket: WALLACH=5B
NECROSIS FACTOR BINDING	)	
PROTEIN II, AND VECTORS,	)	
HOSTS AND PROCESSES USING	)	
SUCH DNA	)	

21/H  
183  
5/31/99  
(NE)

RECEIVED

AMENDMENT

AUG 27 2000

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Official Action of February 26, 1999, please amend as follows:

IN THE CLAIMS

Rewrite claim 11 (four-times amended) in five-times amended form as follows:

11 (Five-times amended). An isolated DNA molecule comprising a contiguous nucleotide sequence coding for a protein consisting of naturally occurring human Tumor Necrosis Factor (TNF) Binding Protein II, herein designated TBP-II, said TBP-II including[, at the N-terminal region thereof,] the amino acid sequence: Thr-Pro-Tyr-Ala-Pro-Glu-Pro-Gly-Ser-Thr in the portion of the protein sequenced by N-terminal sequence analysis, said protein having the ability to inhibit the cytotoxic effect of TNF, wherein said naturally occurring TBP-II protein is the same as that protein having the ability to inhibit the cytotoxic